Ciclosporin A and Acute Myocardial Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00403728|
Recruitment Status : Unknown
Verified April 2007 by Hospices Civils de Lyon.
Recruitment status was: Active, not recruiting
First Posted : November 27, 2006
Last Update Posted : April 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction||Drug: ciclosporine A||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Protection by Ciclosporine A During Reperfused Acute Myocardial Infarction.|
|Study Start Date :||September 2004|
- Infarct size evaluated primarily by the area under the curve of CK and troponin I release over the first 72 hours of reperfusion.
- Myocardial contractile reserve assessed by dobutamine echocardiography at day 5.
- No reflow evaluated by MRI at day 5
- Recovery of myocardial contraction assessed by echocardiography and MRI at month 3
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00403728
|Lyon, France, 69677|
|Principal Investigator:||Michel Ovize, MD||Hospices Civils de Lyon|